Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
This article was originally published in The Tan Sheet
Executive Summary
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says
You may also be interested in...
Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA
Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts
OTC Switch Pathway Abroad Looks Smoother, But Payoffs Are Lower
Switching new Rx drug categories to OTC abroad may appeal to firms put off by the trickle of switches in the U.S., but the payoff abroad is smaller and there is no guarantee FDA will follow another government's decision, experts say
Plan B Lightning May Strike Again: Complying Will Not End Political Storm
Perpetual political lightning rod - and emergency contraceptive - Plan B has another chance to draw strikes to FDA as the agency has chosen to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the counter setting